Biotech Values

[rstor1]

This is for all of the obesity fans out here:

http://biz.yahoo.com/prnews/040629/nytu102_1.html

Nastech Pharmaceutical Company Inc. (Nasdaq: NSTK - News) today announced results from a randomized, double blind, placebo controlled Phase 1-C dose-sequencing study of Nastech's PYY3-36 Nasal Spray for obesity, indicating the investigational product reduces caloric intake, demonstrates weight loss over the study, and is safe and well tolerated in clinically obese men and women.

You don't often see a double-blind PI, but I suppose that the psych factor plays a large part in obesity trials

...

Results from the Phase 1-C trial demonstrate a significant, sustained caloric reduction following PYY administration. Subjects in the treatment group receiving PYY before each meal had a reduction in 24-hour calorie intake that started immediately following treatment and continued to decrease over the six treatment days of the study. By the last day of the study, the group receiving PYY before each meal had reduced daily calorie intake by an average of 648 calories. The 24-hour caloric reduction over all days of treatment was related to the number of daily PYY administrations, with those receiving one dose experiencing a mean caloric reduction of 77 calories per day, two doses producing a 197 calorie reduction and those receiving PYY three times daily experiencing an average caloric reduction of 490 calories per day. In addition, subjects who reduced calorie intake following PYY treatment did not compensate by consuming a greater number of calories at subsequent meals.

Results also indicated that treatment with nasal PYY may result in weight loss. Subjects receiving PYY three times a day recorded a weight reduction of 1.3 pounds over the six day course of the study, a rate, if sustained which would be greater than six pounds in a month. Additionally, evidence of an approximate 6 percent average reduction in serum cholesterol levels was recorded among this subject group over the course of the study.

nice dose-dependent results, but the stock gained about 2% on the news. I sold some DNDN bought some NSTK